- Medical School - University of Kansas School of Medicine (1995-1999)
- Residency - University of Kansas Medical Center (1999-2003), Internal Medicine
- Fellowship - University of Kansas Medical Center (2003-2006), Pulmonary Medicine
Sonja Bartolome, M.D.
- Internal Medicine - Pulmonary Disease
- Lung (Pulmonary) Disorders
- Lung Transplant Medicine
Sonja Bartolome, M.D., is a Professor in UT Southwestern Medical Center's Department of Internal Medicine. She specializes in pulmonary hypertension and chronic thromboembolism and is Medical Director of the Chronic Thromboembolic Pulmonary Hypertension Program.
Dr. Bartolome received her medical degree from the University of Kansas School of Medicine, where she also completed her residency in internal medicine, was a chief resident, and then completed a fellowship in pulmonary and critical care medicine.
Prior to joining UT Southwestern in 2010, she was an Assistant Professor of Pulmonary and Critical Care Medicine at the University of Kansas.
In addition to treating patients, Dr. Bartolome researches new treatments for pulmonary hypertension, as well as better ways to use existing medications to treat the disease.
Texas Monthly has named Dr. Bartolome a Super Doctor for several years, including in 2018. She is board certified in internal medicine, pulmonary disease, and critical care medicine by the American Board of Internal Medicine.
Meet Dr. Bartolome
Pulmonary Hypertension Specialist
Pulmonary arterial hypertension became an interest for Sonja Bartolome, M.D., early in her career, when she was a medical intern.
“One night on-call, I admitted a young woman to the hospital who was born on the same day as I, yet had this debilitating disease about which I had learned very little in medical training,” Dr. Bartolome says. “I spent the night studying the problem and have been striving to help those with this disease ever since.”
"Pulmonary hypertension is treatable, and it’s worth treating.”
A rare disease, pulmonary hypertension is abnormally high blood pressure in the arteries of the lungs. The small blood vessels in the lungs “plug up” over time.
The right side of the heart, which pumps the blood through the lungs, then has trouble pumping against these plugged-up blood vessels. People who suffer from this disease have great difficulty breathing, as the right side of the heart begins to tire and eventually fail.
“By the time they come to see us, patients are usually short of breath most of the time and unable to live their lives normally,” Dr. Bartolome says.
Pulmonary hypertension is a chronic disease with no cure. Untreated, it can result in death within five years. But Dr. Bartolome and UT Southwestern Medical Center’s Pulmonary Hypertension team can help find the right treatment for each individual with this disease, which helps the person not only live longer but also have better quality of life.
“Our goal of treatment is to help our patients breathe well enough to get back to their lives. That could mean being able to leave the house, attend a yearly fishing trip, or get back to Zumba class,” she says.
UT Southwestern has one of the largest pulmonary hypertension centers in the country. Dr. Bartolome and her colleagues see more cases of pulmonary hypertension than most other doctors. As a result, they offer experience and specialized care not available in many parts of the country.
Named a Rising Star by Texas Monthly from 2012 to 2014, and as a Super Doctor from 2015 to 2018, Dr. Bartolome also helps develop better treatment options for pulmonary hypertension patients through clinical trials. UT Southwestern often participates in as many as 20 clinical trials at once to try to find new and better ways to treat this progressive disease.
In addition to her work with pulmonary hypertension patients, Dr. Bartolome specializes in the pulmonary complications of liver disease. Patients with liver disease may develop pulmonary hypertension, low oxygen levels, fluid around the lungs, and heart problems.
As the Director of a new Chronic Thromboembolic Pulmonary Hypertension (CTEPH) program, she works with a multi-specialty team to perform curative procedures such as pulmonary thromboendarterecomy (PTE) surgery or balloon pulmonary angioplasty (BPA). Through these procedures, formerly breathless patients may return to exercise and a better quality of life.
Whether working to improve the care of patients with pulmonary hypertension or with chronic thromboembolic disease, Dr. Bartolome is committed to providing cutting-edge, compassionate care for those with chronic illness.
- American College of Chest Physicians
- American Medical Association
- American Thoracic Society
- Pulmonary Hypertension Clinicians and Researchers
- Society of Critical Care Medicine
- Max S Allen Clinical Scholar Award 2006, Dept. Of Internal Medicine, University of Kansas
- Alpha Omega Alpha 2005, Medical Honor Society
Sildenafil for pulmonary arterial hypertension.
Bartolome SD, Channick RN Future cardiology 2006 Mar 2 2 137-43
Deferoxamine mimics the pattern of hypoxia-related injury at the microvasculature.
Bartolome S, Dhillon NK, Buch S, Casillan AJ, Wood JG, O'Brien-Ladner AR, Shock (Augusta, Ga.) 2009 May 31 5 481-5
Portopulmonary Hypertension: A Survey of Practice Patterns and Provider Attitudes.
DuBrock HM, Salgia RJ, Sussman NL, Bartolome SD, Kadry Z, Mulligan DC, Jenkins S, Lackore K, Channick RN, Kawut SM, Krowka MJ, Transplantation direct 2019 Jun 5 6 e456
EXPRESS: Long term study of oral treprostinil to treat pulmonary arterial hypertension: dosing, tolerability, and pharmacokinetics.
White RJ, Parikh K, Allen R, Feldman J, Jerjez-Sanchez C, Pan L, Keogh AM, Vizza CD, Shapiro SM, Gordon K, Broderick M, Bartolome S, Pulmonary circulation 2019 Jul 2045894019866335
Clinical microbiological case: esophago-airway fistula in an AIDS patient.
Bartolome S, Klotz SA, Bartholomew W, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2002 Mar 8 3 189-90
Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension.
Sanampudi S, Bartolome S, Kalva S, Journal of vascular and interventional radiology : JVIR 2019 Jul 30 7 1081
Activated protein C attenuates microvascular injury during systemic hypoxia.
Bartolome S, Wood JG, Casillan AJ, Simpson SQ, O'Brien-Ladner AR, Shock (Augusta, Ga.) 2008 Mar 29 3 384-7
- Sildenafil for pulmonary arterial hypertension.
- Lung (Pulmonary) Disorders
- Lung Transplant Medicine
- Pulmonary Hypertension